DRUGNasdaqPharmaceutical PreparationsFiscal year ends September 30
BRIGHT MINDS BIOSCIENCES INC.
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 40-F on Dec 23, 2025
$53.82+2.52 (+4.91%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Bright Minds Biosciences has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Bright Minds Biosciences filed with the SEC
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
NOTICE AND ACCESS NOTIFICATION TO SHAREHOLDERS
EX-99.2 to Form 6-K
(as at February 10, 2026, except as otherwise noted)
EX-99.3 to Form 6-K
To: All Canadian Securities Regulatory Authorities
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF US$175 MILLION PUBLIC OFFERING
EX-99.1 to Form 6-K
Piper Sandler & Co., and
EX-99.1 to Form 6-K
Registration Statement on Form F-3
EX-99.2 to Form 6-K
BRIGHT MINDS BIOSCIENCES ANNOUNCES LAUNCH OF US$100 MILLION PUBLIC OFFERING
EX-99.1 to Form 6-K
BRIGHT MINDS BIOSCIENCES EXPANDS SCIENTIFIC ADVISORY BOARD TO INCLUDE
EX-99.1 to Form 6-K
Bright Minds Biosciences to Present at Upcoming Conferences
EX-99.1 to Form 6-K
BRIGHT MINDS BIOSCIENCES INITIATES NEW PRADER-WILLI SYNDROME (PWS)
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K
Condensed Interim Consolidated Financial Statements
EX-99.1 to Form 6-K